Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

News & Events

Breadcrumb

  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 30 May 2023

    ORYZON to present positive preclinical efficacy data of ORY-4001 in Charcot-Marie-Tooth (CMT) disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

  • 17 May 2023

    ORYZON to present trial in progress Phase Ib FRIDA study at the upcoming 2023 ASCO annual meeting

  • 10 May 2023

    ORYZON reports financial results and corporate update for quarter ended March 31, 2023

  • 9 May 2023

    ORYZON to give updates on corporate progress in May-June

  • 3 April 2023

    ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder

  • 15 March 2023

    ORYZON announces First Patient In in FRIDA, a Phase Ib trial with iadademstat in relapsed/refractory FLT3-mutant acute myeloid leukemia patients

  • 13 March 2023

    ORYZON announces clinical candidate nomination of ORY-4001 for the treatment of CNS disorders

  • 22 February 2023

    ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology

  • 17 February 2023

    ORYZON reports financial results and corporate update for quarter ended December 31, 2022

  • 6 February 2023

    ORYZON to give updates on corporate progress in February-March

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Next page Next ›
  • Last page Last »

Email alerts

Subscribe and stay up to date with our latest news

Subscribe

We count on your participation in the ORDINARY GENERAL SHAREHOLDERS’ MEETING of Oryzon. Vote or delegate your vote at https://oryzon.juntadeaccionistas.es/en and you will receive as a gift a wireless headphones that combine technology, sustainability and design for an enjoyable music experience.

Remember, you can get them if you participate in person.

auriculares

Vote or delegate
your vote: HERE 

June 26
at 12:00 h.  

Gómez-Acebo & Pombo Abogados.
Pº de la Castellana, 216 (Torre Realia),
28046, Madrid.

Shareholders contact service:
Email: [email protected]
Phone: 937074100

logo
qr
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy